A Dose-response Study of Dietary Resveratrol on Lipid Metabolism Disorder

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 168 participants.

Also called NCT04886297

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; double masking; primary purpose prevention
Phase
Phase 3
Enrolled
  • 168 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT04886297
Other papers using this trial's data
  • A Randomized Trial on Resveratrol Supplement Affecting Lipid Profile and Other Metabolic Markers in Subjects with Dyslipidemia Nutrients, 2023-01-17 DOI, PubMed 36771199, PMC9921501 In the PMC Open Access subset under CC BY.

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
China (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT04886297. Randomized; double masking; primary purpose prevention. Start 2021-05-01 (actual); primary completion 2022-05-30 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
A Dose-response Study of Dietary Resveratrol on Lipid Metabolism Disorder
Condition
Dyslipidemias
Intervention (Drug)
Mega Resveratrol® capsules
Intervention (Drug)
Mega Resveratrol® Placebo capsules
Lead sponsor
Sun Yat-sen University (class: other)

Record details

Record id
cardio:ct-nct04886297
Content hash
9a8f1777522a97cc580829575e10f119cdfcd1f859d82ba1e6995a8669262200